ITM Announces Phase 3 COMPETE Patient-Reported Quality of Life Data with n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11) vs. Everolimus at ASCO 2026 - The Manila Times

ITM Announces Phase 3 COMPETE Patient-Reported Quality of Life Data with n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11) vs. Everolimus at ASCO 2026    The Manila Times 177Lu-edotreotide Improves HRQOL vs Everolimus in GEP-NETs    CancerNetwork Molecular Targeting Technologies Reports Clinical Data Supporting Two-Cycle EBTATE and Enhanced Tumor Targeting in GEP-NET Patients at SNMMI 2026    Yahoo Finance ITM to present COMPETE trial dosimetry data at SNMMI 2026    AuntMinnie ITM Announces Phase 3 COMPETE Patient-Reported Quality of Life Data with n.c.a. ...    Caledonian Record

Original source: Google News